Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1805 results
April 2021
-
Media ReleaseNovartis signs initial agreement to reserve capacity and implement the technology transfer for the production of the active pharmaceutical ingredient for Roche’s Actemra/RoActemra®Initial agreement covers reservation of the large-scale state-of-the-art biologics facility in Singapore site for the production of the active pharmaceutical ingredient for Roche’s Actemra/RoActemra…
-
Bringing Chagas disease to people’s attention
Explaining Chagas disease through the stories of patients in Bolivia.
-
Featured NewsWorld Chagas Disease Day 2021
Together with partners, Novartis is committed to reimagining the fight against Chagas disease and advocating for an integrated, end-to-end care approach.
March 2021
-
Media ReleaseNovartis receives EU approval for Kesimpta® (ofatumumab), the first and only self-administered, targeted B-cell therapy for adult patients with relapsing multiple sclerosisThere are more than 1 million people living with multiple sclerosis (MS) in Europe1, Kesimpta® (ofatumumab) addresses the current unmet need for a high-efficacy disease-modifying therapy (DMT) that…
-
Media ReleaseNovartis expands targeted radioligand therapy pipeline with in-license for compounds targeting Fibroblast Activation Protein (FAP)Expands Novartis Oncology radioligand pipeline with exclusive worldwide rights to develop and commercialize therapeutic applications for a library of FAP assets including FAPI-46 and FAPI-74Broad…
-
Key ReleaseNovartis announces positive result of phase III study with radioligand therapy 177Lu-PSMA-617 in patients with advanced prostate cancerPhase III VISION study with 177Lu-PSMA-617 met both primary endpoints, significantly improving overall survival (OS) and radiographic progression-free survival (rPFS) in patients with PSMA-positive…
-
Featured NewsNovartis inaugurates innovative watershed project in India to increase water availability
Together with local partners, Novartis aims to initiate a watershed development project near its own and supply chain operations in the Telangana region.
-
Novartis joins pharma-wide effort to meet global demand for COVID-19 vaccines
A conversation with Joachim Momm, head of a Novartis manufacturing site that will be helping to produce Pfizer-BioNTech vaccine doses.
-
Key ReleaseNovartis appoints Karen Hale as Chief Legal OfficerBasel, March 22, 2021 — Novartis announced today the appointment of Karen L. Hale as Chief Legal Officer. She will report to Vas Narasimhan, M.D., CEO of Novartis and become a member of the Executive…
-
Featured NewsHighlights from the Co-Creating Impact Summit 2020
The Co-Creating Impact Summit 2020 was a succesful event with important steps on our work of improving our impact on the society and the planet.
-
Media ReleaseNew Zolgensma data demonstrate age-appropriate development when used early, real-world benefit in older children and durability 5+ years post-treatmentChildren with SMA treated presymptomatically achieved age-appropriate motor milestones including sitting, standing and walking; required no ventilatory or feeding tube support; and had no serious,…
-
Key ReleaseNovartis provides update on Phase III study evaluating canakinumab (ACZ885) as second or third-line treatment in combination with chemotherapy in non-small cell lung cancerPhase III CANOPY-2 trial did not meet primary endpoint of overall survival in patients with advanced or metastatic non-small cell lung cancer whose cancer progressed…
Pagination
- ‹ Previous page
- 1
- …
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- …
- 151
- › Next page